“Spesolimab Improves Quality of Life in Generalized Pustular Psoriasis (GPP) As Measured by Proportion of Patients With Dermatology Life Quality Index (DLQI) Scores of 0 or 1 and Reduction in Pain Severity Over Time: Results From the EFFISAYIL® 2 Trial”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s652, https://doi.org/10.25251/fmm5fj59.